0001415889-24-001829.txt : 20240125 0001415889-24-001829.hdr.sgml : 20240125 20240125200009 ACCESSION NUMBER: 0001415889-24-001829 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240123 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILSON ROBERT N CENTRAL INDEX KEY: 0001189022 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 24563784 MAIL ADDRESS: STREET 1: C/O JOHNSON & JOHNSON STREET 2: ONE JOHNSON PLAZA CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 4 1 form4-01252024_080102.xml X0508 4 2024-01-23 0001534133 CalciMedica, Inc. CALC 0001189022 WILSON ROBERT N C/O CALCIMEDICA, INC. 505 COAST BLVD. S. #307 LA JOLLA CA 92037 true false false false 0 Common Stock 2024-01-23 4 A 0 68314 4.2665 A 250475 D Warrant 5.36 2024-01-23 4 A 0 34157 0.125 A 2024-01-23 2024-12-31 Common Stock 34157 34157 D Warrant 7.15 2024-01-23 4 A 0 34157 0.125 A 2024-01-23 2026-12-31 Common Stock 34157 34157 D The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. /s/ John Dunn, Attorney-in-Fact 2024-01-25